Simple urine test could help HIV-Negative women stick to PrEP
NCT ID NCT03935464
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a new urine test that measures tenofovir levels to see how well HIV-negative women are taking their daily PrEP medication. Researchers provided real-time feedback based on the test results, along with standard counseling, to 100 women. The goal was to see if this approach is acceptable and feasible for improving adherence to PrEP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
urine-based tenofovir adherence assay (behavioral intervention with feedback)
What this could lead to
If successful, this could provide a simple, real-time urine test to help people on PrEP stay adherent and reduce HIV risk.
What could go wrong
This is a small pilot study (100 participants) focused on feasibility, not effectiveness. The test may not improve adherence in larger, more diverse populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RISK REDUCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KEMRI Partners in Health and Research Development (PHRD), Thika
Thika, Near Nairobi, Kenya